TCG Crossover

TCG Crossover, also known as TCGX, is a venture capital firm dedicated to advancing disruptive medicines and supporting companies that can improve the lives of patients. The firm invests in both private and public companies, focusing on innovative biotech ventures. With offices in Palo Alto, San Francisco, and New York City, TCGX has global capabilities and has supported companies in North America, Europe, and China. The firm operates out of closed-end funds, allowing for patient capital and long-term partnerships with portfolio companies. TCGX's investment strategy emphasizes collaboration, leveraging a network of scientific advisors and operational executives to provide guidance on the challenges of drug development. The firm's portfolio includes investments in companies such as Arbor Biotechnologies, Aviceda Therapeutics, Adcendo, Vicebio, Candid Therapeutics, Pathalys Pharma, Beacon Therapeutics, Pheon Therapeutics, Obsidian Therapeutics, and COMPASS Pathways. In October 2025, TCGX closed its third fund, raising $1.3 billion and bringing its total capital to $3.1 billion, underscoring its growing influence in the biotechnology investment landscape. The firm's leadership includes Dr. Chen Yu, founder and managing partner, and Giuliano Marostica, who was promoted to managing partner in October 2025. TCGX's mission is to back visionary entrepreneurs and companies advancing disruptive medicines to improve patient outcomes.

TCGX focuses on innovative biotech companies that leverage recent scientific breakthroughs to develop transformative medicines. The firm invests across various stages, from seed to pre-IPO, and has a global investment scope, including North America, Europe, and China. TCGX's investment strategy emphasizes collaboration, leveraging a network of scientific advisors and operational executives to provide guidance on the challenges of drug development. The firm's portfolio includes investments in companies such as Arbor Biotechnologies, Aviceda Therapeutics, Adcendo, Vicebio, Candid Therapeutics, Pathalys Pharma, Beacon Therapeutics, Pheon Therapeutics, Obsidian Therapeutics, and COMPASS Pathways. In October 2025, TCGX closed its third fund, raising $1.3 billion and bringing its total capital to $3.1 billion, underscoring its growing influence in the biotechnology investment landscape. The firm's leadership includes Dr. Chen Yu, founder and managing partner, and Giuliano Marostica, who was promoted to managing partner in October 2025. TCGX's mission is to back visionary entrepreneurs and companies advancing disruptive medicines to improve patient outcomes.

TCGX focuses on innovative biotech companies that leverage recent scientific breakthroughs to develop transformative medicines. The firm invests across various stages, from seed to pre-IPO, and has a global investment scope, including North America, Europe, and China. TCGX's investment strategy emphasizes collaboration, leveraging a network of scientific advisors and operational executives to provide guidance on the challenges of drug development. The firm's portfolio includes investments in companies such as Arbor Biotechnologies, Aviceda Therapeutics, Adcendo, Vicebio, Candid Therapeutics, Pathalys Pharma, Beacon Therapeutics, Pheon Therapeutics, Obsidian Therapeutics, and COMPASS Pathways. In October 2025, TCGX closed its third fund, raising $1.3 billion and bringing its total capital to $3.1 billion, underscoring its growing influence in the biotechnology investment landscape. The firm's leadership includes Dr. Chen Yu, founder and managing partner, and Giuliano Marostica, who was promoted to managing partner in October 2025. TCGX's mission is to back visionary entrepreneurs and companies advancing disruptive medicines to improve patient outcomes.